BioLargo, Inc. (OTCQX:BLGO) reported its financial results for the third quarter ended September 30, 2026, while outlining progress across its medical, consumer, water treatment and energy businesses. The company reported lower nine-month revenue, continued net losses and increased operating cash use as Clyra Medical invested ahead of an additional product line expected in 2027.
#Third-quarter financial results
BioLargo recorded total revenue of $1,090,000 in the third quarter of 2026, compared with $1,103,000 a year earlier, a decrease of 1%. Service revenue increased 72%, while product revenue decreased 32%.
The company reported a third-quarter net loss of $3,824,000, compared with $7,244,000 in the same period of the previous year, a decrease of 47%. BioLargo said the comparison was primarily affected by a credit loss expense incurred last year.
For the nine months, total revenue was $3,452,000, compared with $7,148,000, a decrease of 52%. Service revenue increased 23%, while product revenue decreased 73%. The nine-month net loss was $11,229,000, compared with $11,047,000, an increase of 2%.
#Cash use and financing
Net cash used in operating activities reached $8,182,000 during the first nine months of 2026, compared with $6,707,000 in the same period of 2025, an increase of 22%. During the third quarter, operating cash use averaged roughly $736,000 per month, compared with roughly $996,000 per month in the first half of 2026.
Clyra Medical raised $4,299,000, primarily through a debt offering, while BioLargo’s battery subsidiary, BETI, sold $487,000 in stock. BioLargo said 77% of the capital was raised at subsidiary level. The parent company sold $1,359,000 in common stock, partly through the Clearthink purchase agreement.
Clyra accounted for approximately 57% of the consolidated nine-month net loss. The subsidiary’s spending covered personnel, manufacturing, product development and clinical activities. BioLargo said the debt used to finance much of this work also increased interest expense.
The operating loss of BioLargo’s corporate segment declined 27% for the nine months to $2,200,000 from $3,034,000.
#Clyra Medical expands ViaCLYR distribution
Clyra Medical has focused its 2026 sales activity on developing distribution for ViaCLYR, its wound irrigation product. The subsidiary signed agreements with Advanced Solution for the U.S., Al-Hikma FZCO for international distribution and Spartan Medical for U.S. Government and military distribution.
Clyra also invested in manufacturing capabilities, product design, market testing, clinical work, personnel and commercial outreach. The company said these efforts are intended to support existing distributors and prepare for a national rollout of an additional product line expected in 2027 with a confidential strategic partner.
During the third quarter, Clyra also satisfied a contractual milestone under an exclusive distribution agreement for certain products.
#BioLargo launches barebird consumer products
In October 2026, BioLargo launched consumer odor-control products under its company-owned barebird brand through BioLargo CPG LLC. The line focuses on pet and laundry odors and features the company’s CupriDyne Clean technology.
BioLargo said the products do not require fragrances. The company also described digital marketing activities using AI selling tools to help direct marketing spending.
#PFAS treatment and engineering operations
BioLargo’s Aqueous Electrostatic Concentrator, or AEC, has been removing PFAS from municipal drinking water in Lake Stockholm, New Jersey, since January. The Environmental Protection Agency and the New Jersey equivalent continue to monitor the system’s performance against state and federal standards.
The company said it has submitted bids and proposals, received indications of interest from different types of customers and begun discussions with firms whose PFAS treatment product lines have identified gaps. BioLargo also added industry experts to its team.
BioLargo Engineering increased revenue by 23% while supporting PFAS work and Cellinity projects. BioLargo Energy, which is focused on the Cellinity industrial grid-scale battery, and Tu Nipi, which works on water treatment for Canadian oil sands tailings water, are discussing potential strategic partners to invest and work with them on commercial operations.
#2027 plans and risk disclosures
CEO Dennis P. Calvert said BioLargo is preparing for 2027 with additional medical products and sales channels, the recently launched barebird line and commercial relationships in the water and energy industries. He said the company expects spending in 2027 to move away from research and development and toward sales generation.
These statements are subject to the risks identified by BioLargo, including its history of net losses, the need for additional financing, uncertainty over when it may become profitable, reliance on third-party marketing partners, manufacturers and suppliers, and the absence of minimum purchase commitments from most customers. The company also cited risks involving market acceptance, FDA, EPA, state and foreign regulatory approvals, competition, dilution, thin trading on the OTCQX, price volatility and penny stock rules.
#Annual meeting scheduled for December 1
BioLargo will hold its Annual Meeting of Stockholders on December 1, 2026, beginning at 10:00 a.m. Pacific Time in Aliso Viejo, California. The company said it will not hold a quarterly earnings call because of the annual meeting.
#Key Takeaways
- Third-quarter revenue was $1,090,000 and net loss was $3,824,000.
- Nine-month revenue fell to $3,452,000, while the net loss was $11,229,000.
- Clyra Medical represented approximately 57% of the nine-month consolidated net loss and expanded ViaCLYR distribution.
- BioLargo launched barebird odor-control products and continued AEC PFAS treatment work in New Jersey.
- The Annual Meeting of Stockholders is scheduled for December 1, 2026, in Aliso Viejo, California.
Original source: Read original article